Evidence map›Paper›PMID 33475759›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2021

Investigation of a new oxazolidine derivative in human resistance acute leukemia cells: deciphering its mechanism of action by label-free proteomic.

Lidiane Vasconcelos do Nascimento Carvalho, Wanessa Layssa Batista de Sena, Eliana Abdelhay, Michelly Cristiny Pereira, Maira Galdino da Rocha Pitta, Maria do Carmo Alves de Lima, Gustavo Henrique Martins Ferreira Souza, Luciana Pizzatti, Ivan da Rocha Pitta, Moacyr Jesus Barreto de Melo Rêgo

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Lidiane Vasconcelos do Nascimento CarvalhoResearch Center for Therapeutic Innovation (NUPIT-SG), Federal University of Pernambuco, Professor Moraes Rêgo s/n, Cidade Universitária, Recife, Pernambuco, 50670-901, Brazil.
Wanessa Layssa Batista de SenaResearch Center for Therapeutic Innovation (NUPIT-SG), Federal University of Pernambuco, Professor Moraes Rêgo s/n, Cidade Universitária, Recife, Pernambuco, 50670-901, Brazil.
Eliana AbdelhayBone Marrow Transplant Center, National Institute of Cancer, INCA, Rio de Janeiro, Brazil.
Michelly Cristiny PereiraResearch Center for Therapeutic Innovation (NUPIT-SG), Federal University of Pernambuco, Professor Moraes Rêgo s/n, Cidade Universitária, Recife, Pernambuco, 50670-901, Brazil.
Maira Galdino da Rocha PittaResearch Center for Therapeutic Innovation (NUPIT-SG), Federal University of Pernambuco, Professor Moraes Rêgo s/n, Cidade Universitária, Recife, Pernambuco, 50670-901, Brazil.
Maria do Carmo Alves de LimaDrug Planning and Synthesis Laboratory, Federal University of Pernambuco, Recife, Brazil.
Gustavo Henrique Martins Ferreira SouzaDepartment of Mass Spectrometry Research and Development, SpectraMass, Campinas, São Paulo, Brazil.
Luciana PizzattiMolecular Biology and Proteomics of Blood Laboratory, LBCD-LADETEC, Institute of Chemistry, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Ivan da Rocha PittaResearch Center for Therapeutic Innovation (NUPIT-SG), Federal University of Pernambuco, Professor Moraes Rêgo s/n, Cidade Universitária, Recife, Pernambuco, 50670-901, Brazil.
Moacyr Jesus Barreto de Melo RêgoResearch Center for Therapeutic Innovation (NUPIT-SG), Federal University of Pernambuco, Professor Moraes Rêgo s/n, Cidade Universitária, Recife, Pernambuco, 50670-901, Brazil. moacyr.rego@ufpe.br.ORCID 0000-0002-1883-6012
Universidade Federal de Pernambuco · BRInstituto Nacional de Câncer - INCA · BRUniversidade Federal do Rio de Janeiro · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present study aimed to evaluate the mechanism of action of the antineoplastic activity of an oxazolidine derivative, LPSF/NB-3 (5-(4-cloro-benzilideno)-3-etil-2-tioxo-oxazolidin-4-ona). Cytotoxicity assays were performed in peripheral blood mononuclear cells (PBMCs) and resistant acute leukemia cell line (HL-60/MX1) by the MTT method. LPSF/NB-3 exhibited cytotoxicity in HL-60/MX1, but it was not toxic to healthy cells in the highest dose tested (100 μM). The protein extract of HL-60/MX1 cells treated with LPSF/NB-3 was subjected to proteomic analysis using two-dimensional chromatography coupled to mass spectrometry. We could identify a total of 2652 proteins, in which 633 were statistically modulated. Within the group of protein considered for the quantitative analysis with the established criteria, 262 were differentially expressed, 146 with increased expression and 116 with decreased expression in the sample treated with LPSF/NB-3 compared to the control. The following differentially expressed pathways were found: involving regulation of the cytoskeleton, DNA damage, and transduce cellular signals. Networks that were highlighted are related to the immune system. The ELISA technique was used to assess the immunomodulatory potential of LPSF/NB-3 in PBMCs. We observed significant decrease of IFNγ (p < 0.01) and dose-response pattern of the cytokines IL-6, IL-17A, IL-22, and IL-10. Therefore, results suggest that LPSF/NB-3 appears to modulate important pathways, including cell cycle and immune system regulatory pathways.

Indexed as

Antineoplastic AgentsCell CycleCytokinesDose-Response Relationship, DrugDrug Resistance, NeoplasmHL-60 CellsHumansLeukemia, Promyelocytic, AcuteLeukocytes, MononuclearOxazolesProteomicsSignal TransductionAntineoplastic AgentsCytokinesOxazolesoxazolidineCancerCytokinesImmunomodulationMolecular prospecting

Identifiers

PMID33475759
OpenAlexW3125607545

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.